Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.

American journal of respiratory and critical care medicine - 1 May 1997

Parkin D P, Vandenplas S, Botha F J, Vandenplas M L, Seifart H I, van Helden P D, van der Walt B J, Donald P R, van Jaarsveld P P

Abstract excerpt

The study was undertaken to show that polymorphic isoniazid elimination in humans is trimodal; that the acetylator genotype and eliminator phenotype of the individual patient are concordant; and that the differences in the pharmacokinetic parameters of fast, intermediate, and slow eliminator subgroups are statistically significant. Sixty adult patients of both sexes and of mixed race with tuberculosis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antitubercular Agents

Share to Arylamine N-Acetyltransferase

Share to NAT2 gene

Share to Genotype

Share to Phenotype

Share to Tuberculosis, Pulmonary

Source

Identifiers

PMID: 9154882
DOI: 10.1164/ajrccm.155.5.9154882

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.PMID 9154882Read ↗

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.Semantic proximity Read ↗

Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.Semantic proximity Read ↗

Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers.Semantic proximity Read ↗

Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.Semantic proximity Read ↗

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.Semantic proximity Read ↗

Population screening for isoniazid acetylator phenotype.Semantic proximity Read ↗

Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.Semantic proximity Read ↗

The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid.Semantic proximity Read ↗

Acetylation Variability in Elderly Tunisians: Implications for Isoniazid Dose Individualization.Semantic proximity Read ↗

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?Semantic proximity Read ↗

Case Study 10: A Case to Investigate Acetyl Transferase Kinetics.Semantic proximity Read ↗

Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.